Book contents
- Frontmatter
- Contents
- Introduction
- How to use this book
- Abbreviations
- Acknowledgements
- DRUGS: AN A–Z GUIDE
- SHORT NOTES
- Routes of administration
- Loading dose
- Drug metabolism
- Enzyme systems
- Drug excretion
- Drug tolerance
- Drug interactions
- Therapeutic drug monitoring
- Target range of concentration
- Pharmacology in the critically ill
- Cardiopulmonary resuscitation
- Drugs in advanced life support
- Management of acute major anaphylaxis
- Management of severe hyperkalaemia
- Management of malignant hyperthermia
- Sedation, analgesia and neuromuscular blockade
- A practical approach to sedation and analgesia
- Opioid Conversion table
- Management of status epilepticus
- Prevention of delirium tremens and alcohol withdrawal syndrome
- Prevention of Wernicke–Korsakoffsyndrome
- Anti-arrhythmic drugs
- Inotropes and vasopressors
- Bronchospasm
- Anti-ulcer drugs
- Immunonutrition in the ICU
- Corticosteroids
- Short synacthen test
- Bone marrow rescue following nitrous oxide
- Antioxidants
- Post-splenectomy prophylaxis
- Anti-microbial drugs
- Bacterial gram staining
- Antibiotics: sensitivities
- Renal replacement therapy
- Extracorporeal drug clearance: basic principles
- Drug doses in renal failure/renal replacement therapy
- Chemical pleurodesis of malignant pleural effusion
- APPENDICES
- DRUG INDEX
- IV COMPATIBILITY CHART
Prevention of Wernicke–Korsakoffsyndrome
Published online by Cambridge University Press: 05 November 2014
Book contents
- Frontmatter
- Contents
- Introduction
- How to use this book
- Abbreviations
- Acknowledgements
- DRUGS: AN A–Z GUIDE
- SHORT NOTES
- Routes of administration
- Loading dose
- Drug metabolism
- Enzyme systems
- Drug excretion
- Drug tolerance
- Drug interactions
- Therapeutic drug monitoring
- Target range of concentration
- Pharmacology in the critically ill
- Cardiopulmonary resuscitation
- Drugs in advanced life support
- Management of acute major anaphylaxis
- Management of severe hyperkalaemia
- Management of malignant hyperthermia
- Sedation, analgesia and neuromuscular blockade
- A practical approach to sedation and analgesia
- Opioid Conversion table
- Management of status epilepticus
- Prevention of delirium tremens and alcohol withdrawal syndrome
- Prevention of Wernicke–Korsakoffsyndrome
- Anti-arrhythmic drugs
- Inotropes and vasopressors
- Bronchospasm
- Anti-ulcer drugs
- Immunonutrition in the ICU
- Corticosteroids
- Short synacthen test
- Bone marrow rescue following nitrous oxide
- Antioxidants
- Post-splenectomy prophylaxis
- Anti-microbial drugs
- Bacterial gram staining
- Antibiotics: sensitivities
- Renal replacement therapy
- Extracorporeal drug clearance: basic principles
- Drug doses in renal failure/renal replacement therapy
- Chemical pleurodesis of malignant pleural effusion
- APPENDICES
- DRUG INDEX
- IV COMPATIBILITY CHART
Summary
On admission, administer parenteral Pabrinex® (p. 176) to all alcoholdependent patients undergoing inpatient alcohol withdrawal, or to those patients who are thought to be severely thiamine deficient. Pabrinex® contains vitamins B and C but we are using it for the thiamine content. Pabrinex® should be administered before any parenteral glucose is given.
Prevention of Wernicke's encephalopathy: ONE pair of Pabrinex® IVHP 5-ml ampoules once or twice daily for 3–5 days.
Therapeutic treatment for Wernicke's encephalopathy: TWO pairs of Pabrinex® IVHP ampoules three times daily for 3 days then review. If no response, discontinue therapy; if a response is seen, decrease dose to ONE pair daily given for as long as improvement continues.
When the Pabrinex® course is finished give oral thiamine 50 mg 8 hourly and multivitamins 1–2 tablets daily, usually for the rest of the admission. For severe vitamin B group deficiency, give vitamin B compound strong tablets 1–2 8 hourly. A short course of folic acid 5 mg PO daily may be beneficial.
Information
- Type
- Chapter
- Information
- Handbook of Drugs in Intensive CareAn A-Z Guide, pp. 275Publisher: Cambridge University PressPrint publication year: 2014
Accessibility standard: Unknown
Why this information is here
This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.Accessibility Information
Accessibility compliance for the PDF of this chapter is currently unknown
and may be updated in the future.